Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who have progressive or refractory meningeal tumors.

Key facts

Study ID

NCT00031928

Run by

National Cancer Institute (NCI)

People needed

3000

Starts

2002-01-01

Last updated by the study team

2015-04-30

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital Los Angeles — Los Angeles, California, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Texas Children's Cancer Center — Houston, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Neurological Research Center, Inc. — Bennington, Vermont, United States
• Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.